Phlebologie, Inhaltsverzeichnis

Phlebologie 2004; 33(03): 92-96
DOI: 10.1055/s-0037-1617278

Original Articles

Schattauer GmbH

Pyoderma gangraenosum: erfolgreiche Therapie mit topischer Applikation von Cyclosporin A

Pyoderma gangrenosum: successful treatment with locally applied cyclosporine APyoderma gangrenosum: réussite du traitement par ciclosporine A en application locale

K. Hartmann

Universitätsklinik und Poliklinik für Dermatologie Bonn

,

S. Nagel

Universitätsklinik und Poliklinik für Dermatologie Bonn

,

T. Erichsen

Universitätsklinik und Poliklinik für Dermatologie Bonn

,

T. Bieber

Universitätsklinik und Poliklinik für Dermatologie Bonn

,

E. Rabe

Universitätsklinik und Poliklinik für Dermatologie Bonn

,

F. Pannier

Universitätsklinik und Poliklinik für Dermatologie Bonn

› Institutsangaben

Zusammenfassung

Pyoderma gangraenosum (PG), eine seltene, ulzerierende Hauterkrankung, ist wahrscheinlich durch vaskulitische Prozesse verursacht. In ca. 20 bis 70% der Fälle ist PG mit einer Grunderkrankung assoziiert, am häufigsten mit chronisch-entzündlichen Darmerkrankungen und Erkrankungen des rheumatischen oder hämatologischen Formenkreises. PG kommt auch posttraumatisch als Pathergiephänomen vor.

Der größte Teil der verschiedenen Therapieansätze bei Pyoderma gangraenosum beruht auf systemischer Gabe von Immunsuppressiva. Wir berichten über unsere Therapieerfahrungen mit topischer Applikation von Cyclosporin-A-Lösung.

Summary

Pyoderma gangrenosum (PG) is a rare, ulcerative skin disease, probably caused by vasculitic processes. In 20 to 70% of cases, it is associated with an underlying disease, most commonly inflammatory bowel disease, rheumatological or haematological disease. Additionally, PG occurs in connection with traumatic events. The majority of the numerous concepts known to treat pyoderma gangrenosum include systemic application of immunosuppressants. We report on a two year experience in the treatment of PG with locally applied cyclosporine A solution.

Résumé

Le pyoderma gangrenosum (PG) est une dermatose ulcérative rare, vraisemblablement provoquée par un processus de vascularite. Dans 20 à 70% des cas, PG est associé à des pathologies sous-jacentes, qui sont le plus souvent des maladies inflammatoires chroniques de l’intestin, des rhumatismes inflammatoires ou des affections hématologiques. Par ailleurs, des cas de PG posttraumatiques sont également rapportés.

La majorité des nombreux concepts connus pour traiter pyoderma gangrenosum comprennent l’application systémique d’immunosuppresseurs. Nous décrivons une expérience de deux ans dans le traitement de PG par une solution de ciclosporine A, utilisée en application locale.

Schlüsselwörter

Schlüsselwörter

Pyoderma gangraenosum - Pathergie - Cyclosporin A

Mots clé

Mots clé

Pyoderma gangrenosum - cyclosporine A

Keywords

Keywords

Pyoderma gangrenosum - cyclosporine A

Literatur
1 Breathnach SM, Wells GC, Valdimarsson H. Idiopathic pyoderma gangrenosum and impaired lymphocyte function: failure of azathioprine and corticosteroid therapy. Br J Dermatol 1981; 104: 567-73.
2 Brunsting LA, Goeckermann WH, O’Leary PA. Pyoderma (ecthyma) gangrenosum: clinical and experimental observations in five cases occuring in adults. Arch Dermatol 1930; 22: 655-80.
3 Burruss JB, Farmer E, Callen JP. Chlorambucil is an effective corticosteroidsparing agent for recalcitrant pyoderma gangrenosum. J Am Acad Dermatol 1996; 35: 720-4.
4 Callen JP. Pyoderma gangrenosum. Lancet 1998; 351 9102 581-5.
5 Chow RKP, Ho VC. Treatment of pyoderma gangrenosum. J Am Acad Dermatol 1996; 34: 1047-60.
6 Crowson AN, Mihm Jr MC, Magro C. Pyoderma gangrenosum: a review. J Cutan Pathol 2003; 30: 97-107.
7 De Cock KM, Thorne MG. The treatment of pyoderma gangrenosum with sodium cromoglycate. Br J Dermatol 1980; 102: 231-3.
8 Duncan JI, Payne SN, Winfield AJ. et al. Enhanced percutaneous absorption of a novel topical cyclosporin A formulation and assessment of its immunosuppressive activity. Br J Dermatol 1990; 123: 631-40.
9 Eisen D, Ellis CN. Topical cyclosporine for oral mucosal disorders. J Am Acad Dermatol 1990; 23: 1259-64.
10 Elgart G, Stover P, Larson K. et al. Treatment of pyoderma gangrenosum with cyclosporine; results in seven patients. J Am Acad Dermatol 1991; 24: 83-6.
11 Fradin MS, Ellis CN, Voorhee JJ. Management of patients and side effects during cyclosporine therapy for cutaneous disorders. J Am Acad Dermatol 1990; 23: 1265-73.
12 Gleichmann US, Otte HG, Körfer R. et al. Posttraumatisches Pyoderma gangraenosum: Kombinationstherapie mit intravenösen Immunglobulinen und systemsischen Kortikosteroiden. Hautarzt 1999; 50: 879-83.
13 Gupta AK, Shear NH, Sauder DN. Efficacy of human intravenous immune globulin in pyoderma gangrenosum. J Am Acad Dermatol 1995; 32: 140-2.
14 Hohenleutner U, Mohr VD, Mickel S. et al. Mycophenolate mofetil and cyclosporin treatment for recalcitrant pyoderma gangrenosum. Lancet 1997; 350: 1748.
15 Johnson RB, Lazarus GS. Pulse therapy: therapeutic efficacy in the treatment of pyoderma gangrenosum. Arch Dermatol 1982; 118: 76-84.
16 Lovett GW, Field JP, King Jr LE. Treatment of pyoderma gangrenosum with clofazimine. A case report and review of associated diseases. J Tenn Med Assoc 1981; 74: 567-8.
17 Matis WL, Ellis CN, Griffiths CEM. et al. Treatment of pyoderma gangrenosum with cyclosporine. Arch Dermatol 1992; 128: 1060-4.
18 Moraes M, Russo G. Thalidomide and its dermatologic uses. Am J Med Sci 2001; 321: 321-6.
19 Newell LM, Malkinson FD. Pyoderma gangrenosum: response to cyclophosphamide therapy. Arch Dermatol 1983; 119: 477-86.
20 Nguyen KH, Miller JJ, Helm KF. Case reports and a review of the literature on ulcers mimicking pyoderma gangrenosum. Int J Dermatol 2003; 42: 84-94.
21 Nguyen LQ, Weiner J. Treatment of pyoderma gangrenosum with benzoyl peroxide. Cutis 1977; 19: 842-4.
22 Powell FC, Schroeter AL, Su WPD. et al. Pyoderma gangrenosum: a review of 86 cases. Q J Med 1985; 217: 173-86.
23 Powell FC, Su WPD, Perry HO. Pyoderma gangrenosum: classification and management. J Am Acad Dermatol 1996; 34: 395-409.
24 Prystowsky JH, Kahn SN, Lazarus GS. Present status of pyoderma gangrenosum. Review of 21 cases. Arch Dermatol 1989; 125: 57-64.
25 Reich K, Vente C, Neumann C. Topical tacrolimus for pyoderma gangrenosum. Br J Dermatol 1998; 139: 755-7.
26 Richter-Hintz D, Schuppe HC, Momey B. et al. Topical tacrolimus (FK506) is effective in the treatment of pyoderma gangrenosum. J Am Acad Dermatol 2000; 42: 304-5.
27 Sanders CJ, Hulsmann RF. Successful treatment of pyoderma gangrenosum with topical 5- aminosalicylic acid. Cutis 1993; 51: 262-4.
28 Theissen U, Luger TA, Schwarz T. Successful topical administration of cyclosporin A in pyoderma gangrenosum. Hautarzt 1996; 47: 132-5.
29 Tsele E, Yu RC, AC C. Pyoderma gangrenosum – Response to topical nitrogen mustard. Clin Exp Dermatol 1992; 17: 437-40.
30 Tutuncu Z, Morgan Jr GJ, Kavanaugh A. Anti- TNF therapy for other inflammatory conditions. Clin Exp Rheumatol 2002; 20 6 Suppl 28 146-51.
31 Wenzel J, Gerdsen R, Phillip-Dormston W. et al. Topical treatment of pyoderma gangraenosum. Dermatology 2002; 205: 221-3.
32 Wines N, Wines M, Ryman W. Understanding pyoderma gangrenosum: a review. Med General Med 2001; 27: 6.
33 Wollina U. Clinical management of pyoderma gangrenosum. Am J Clin Dermatol 2002; 3: 149-58.